Inovio Biomedical Corporation Partner Tripep Announces Completion of Phase I DNA Vaccine Study

Published: Nov 30, 2009

Bookmark and Share

SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that its partner Tripep AB of Sweden has completed its phase I clinical study of its ChronVac-C hepatitis C virus DNA vaccine delivered using Inovio’s electroporation technology. The study established the safety and tolerability of this therapy, with vaccine-induced immune responses and transient effects on the serum levels of hepatitis C virus in these chronically infected patients providing proof-of-concept of DNA vaccines delivered using electroporation.

Back to news